3.15 billion in cash "ammunition" in place—can Hansoh Pharmaceutical unlock the global innovative drug market?

Ask AI · How does HanSer BioPharma’s BD strategy balance risk and reward?

Reporter Ji Yuanyuan from 21st Century Business Herald

In the spring of 2026, for China’s innovative drug industry, it is a season to test the “real substance.”

On March 29, HanSer BioPharma (03692.HK) released its 2025 full-year earnings report. At a time when the pharmaceutical industry has gone through a deep freeze in capital markets and when the market has shifted from “valuation hype” to “verifying cash flow,” this set of financials concerns not only a company—it is also viewed as a window into whether leading Chinese innovative drug companies can ride out the cycle.

The financial report shows that during the reporting period, HanSer BioPharma achieved total revenue of approximately RMB150.28 billion, up 22.6% year over year; profit of approximately RMB55.55 billion, up 27.1%. In an environment where the overall growth rate in the pharmaceutical industry is slowing, this double-digit growth rate is already the work of an “outstanding student.”

The real highlight lies in the revenue mix. In 2025, sales revenue from innovative drugs and partnered products at HanSer BioPharma reached RMB123.54 billion, up 30.4% year over year, and for the first time the share of total revenue rose to 82.2%. This ratio is at a leading level among Hong Kong-listed 18A companies and traditional transformation-stage pharmaceutical firms.

This means HanSer BioPharma has basically completed its identity shift from a “generic-drug company” to an “innovation-driven pharmaceutical company.” The share of its former “cash cow” generic-drug segment has been compressed to below 20%, while high-margin, high-barrier innovative drugs have become the core assets that determine the company’s valuation.

In capital markets, when assessing the quality of a pharma company, two indicators are often considered: first, the purity of its innovation; second, the thickness of its cash flow. The latest data from the National Medical Products Administration shows that in Q1 2026, the total value of China’s innovative drug out-licensing transactions to overseas parties has already exceeded $60 billion, nearing half of 2025 for the whole year; as of March 27, this year has approved 10 innovative drugs, including 8 domestically developed products.

For pharma companies, innovation has become an important underlying color.

The BD Double-Edged Sword

The core value of the business of innovative drugs lies in the “high pricing power” brought by “high-tech barriers” and the broad “global market” space. HanSer BioPharma’s growth engine is still driven by its star products. The oncology segment, as the fundamental base, delivered revenue of RMB99.74 billion in 2025, accounting for 66.4%.

The story of the core product Amerron (ametinib) is entering its “second act.” In the domestic market, it already has the highest number of five indications among products in the same category today, and the first four are all included in the National Reimbursement Drug List. However, the “intensified competition” in the domestic third-generation EGFR-TKI market is a fact; the real incremental space comes from overseas.

The financial report shows that Amerron’s internationalization is accelerating— it has obtained approvals from the UK MHRA and the European Commission EC for market listing in succession, becoming the first China-developed original EGFR-TKI to be launched overseas.

Beyond its oncology “anchor,” HanSer BioPharma is building a “second growth curve.” In the central nervous system field, Xinyue (inelizumab) added two indications—IgG4-related diseases and generalized severe myasthenia gravis. In the metabolic space, the GLP-1/GIP dual-target agonist HS-20094 has shown excellent results in Phase III clinical data for obesity or overweight.

A research analyst covering the pharmaceutical industry at a brokerage firm told 21st Century Business Herald that with the patent cliff approaching, MNCs (multinational pharmaceutical companies) have an unprecedented thirst for late-stage pipelines. HanSer BioPharma employs a “dual-wheel drive” through both in-house R&D (such as HS-20094) and acquisitions/imports (such as HS-20137). It has positioned itself across globally popular tracks including ADCs, GLP-1, and autoimmune diseases. This “multi-point flowering” pipeline matrix reduces the risk of dependency on a single product and improves the overall valuation’s certainty.

In 2025, the key word in China’s innovative drug industry is none other than “BD” (business development). If previously China’s BD mainly meant “buy, buy, buy” (license-in), then 2025’s main theme is “sell, sell, sell” (license-out).

Data disclosed by the National Medical Products Administration show that in the first quarter of 2026, transaction value exceeded $60 billion. An industry insider put it bluntly: “He who has BD wins the world. BD’s role in the overall capital supply has become increasingly important.”

HanSer BioPharma is precisely a beneficiary of this trend. In 2025, HanSer BioPharma secured three major licensing deals: granting Regeneron a global exclusive license for the GLP-1/GIP dual-receptor agonist (excluding mainland China and Hong Kong/Macao), totaling $2.01 billion; granting Roche a global exclusive license for the CDH17 ADC drug (excluding the Greater China region), totaling $1.53 billion; and entering a licensing collaboration with Glenmark for Amerron, totaling more than $1 billion.

The three transactions combined exceeded $4.5 billion. What they bring is not only an added supplement to cash flow from upfront payments, but more importantly, “international endorsement.” In the innovative drug business, being recognized by top buyers such as Roche and Regeneron means the scientific value and commercial potential of its pipeline is recognized worldwide.

However, BD is not without risk. With transactions surging, potential disputes are also rising—for example, the arbitration case between Novo Nordisk and Henry Medicine has served as a warning to the industry about “data due diligence.”

The aforementioned analyst said directly: BD is an art of balancing. For HanSer BioPharma, License-out demonstrates its R&D strength and brings cash flow; meanwhile, a moderate License-in (such as pipelines acquired from Quanxin Bio and Pumis) fills technical gaps and accelerates speed.

“The key is that, with the $31.5 billion in cash on hand, HanSer’s next BD strategy may shift from ‘financing for survival’ to ‘strategic M&A for building an ecosystem,’ which will be a focal point for the market in the next stage.”

“Delivering Value” and “Intensified Competition”

At the threshold of the second quarter of 2026, the logic of the innovative drug industry is undergoing a subtle shift.

Looking back at 2025, the industry achieved a leap from “deal heat” to “value realization.” The Shanghai Securities News defined it as the “year of leap.” Looking ahead, competition will revolve around two core areas: the hard-core nature of clinical data and the ability to realize value through commercialization.

For HanSer BioPharma, in 2026 there are multiple catalysts worth watching. On one side, monetization of ADC assets: both the B7-H3 ADC (HS-20093) and the B7-H4 ADC (HS-20089) have received multiple breakthrough therapy designations from the FDA and NMPA. In today’s ADC arena where competition is heating up, selecting differentiated indications (such as osteosarcoma and ovarian cancer) will be key to breaking through.

On the other side, the competitive landscape for GLP-1. As a dual-target agonist, HS-20094 is positioned in what is currently the hottest metabolic track globally. With Eli Lilly, Novo Nordisk, and many domestic competitors pushing forward, whether HanSer can demonstrate better efficacy or safety in Phase III clinical trials will determine its future revenue split proportions and market position.

In addition, there is the game between national medical insurance and commercial insurance. With the rollout of the first edition of the “Innovative Drugs List for Commercial Health Insurance,” high-value innovative drugs are entering a multi-layered reimbursement system under which “basic medical insurance covers essentials and commercial insurance covers innovation.” Whether HanSer’s high-end innovative drugs can capture incremental market share from commercial insurance will directly affect the peak of its domestic sales.

Meanwhile, competitive pressure remains undiminished. In a research report, Guanyuan Securities noted that in 2026, the outlook for the CXO and innovative drug industry chain will continue, but companies with a “high share of overseas orders + strong complex-molecule capability” will have greater advantages. This means that purely “Me-too” drugs have no future; companies must possess global competitiveness.

In fact, HanSer BioPharma’s 2025 financial report is also a microcosm of China’s innovative drug industry moving from “adolescence” toward its “coming-of-age ceremony.”

In the past, the market might have questioned its R&D efficiency or valuation bubble; but now, in the “de-bubbling” cycle of biopharma, cash flow is a company’s lifeline.

The financial report shows that in 2025, HanSer BioPharma’s R&D spending reached RMB33.58 billion, up 24.3% year over year, accounting for about 22.3% of total revenue. With this level of R&D intensity, it can be compared to leading global pharmaceutical companies. With such high investment, the company still maintained abundant cash flow—net cash inflow from operating activities of RMB67.38 billion, and cash and bank deposits at year-end totaling RMB315.49 billion.

This also means HanSer BioPharma has become a “big elephant” with RMB15 billion in revenue, an 82% share of innovative drugs, and RMB31.5 billion in cash.

Of course, challenges still exist: the core product Amerron faces increasingly intense competition; monetization in overseas markets needs to move from “licensing” to the leap toward “self-operated commercialization”; and whether such high R&D spending can be converted into blockbuster breakthroughs still requires time to be validated.

But in any case, HanSer BioPharma’s story proves that when doing innovative drugs in China—though the cycle is long, the investment is large, and the risks are high—once you succeed in riding out the cycle, it is a great business with strong barriers, abundant cash flow, and the ability to reach the world.

For the entire industry, HanSer BioPharma’s 2025 answer sheet undoubtedly lights a beacon for Biotechs that are still holding on through the winter.